Soluble programmed death ligand-1 (sPD-L1) is elevated in aggressive prostate cancer disease among African men

PAUL KATONGOLE (✉ paul.katongole@gmail.com)
Makerere University College of Health Sciences  https://orcid.org/0000-0003-4952-801X

Obondo J. Sande
Makerere University College of Health Sciences

Steven J Reynolds
National Institutes of Health

Moses Joloba
Makerere University College of Health Sciences

Henry Kajumbula
Makerere University College of Health Sciences

Samuel Kalungi
Mulago National Referral Hospital

Kenneth Ssebambulidde
Makerere University Infectious Diseases Institute

Cynthia Nakimuli
Makerere University College of Health Sciences

Maxine Atuheire
Makerere University Infectious Diseases Institute

Jackson Orem
Uganda Cancer Institute

Nixon Niyonzima
Uganda Cancer Institute

Research Article

**Keywords:** Prostate cancer, Immune checkpoint inhibitors, sPD-1, sPD-L1, Immunotherapy

**Posted Date:** November 30th, 2021

**DOI:** https://doi.org/10.21203/rs.3.rs-1107782/v1
Abstract

Background

The programmed death 1 (PD1)/programmed death-ligand 1 (PDL1) targeted immunotherapies have become a new mode of treatment for several tumours; however, there is limited evidence on the expression and prognostic value of PD1/PDL1 in prostate cancer, especially in African men.

Methods

The plasma concentrations of PD-L1/PD1 were assessed using Enzyme-Linked Immunosorbent Assay in patients with prostate cancer and normal healthy controls at the Uganda Cancer Institute. The association between plasma PD-L1/PD1 concentration levels and PSA levels, Gleason scores, age, and Body mass index were determined.

Results

We found significant differences in the median plasma concentrations of PD-L1 and PD-1 immune checkpoint molecules between Prostate cancer cases and normal healthy controls of (0.285 vs 0.035) p-value 0.001 and (0.596 vs 0.355) p-value 0.017, respectively. We found no significant association between age, plasma PSA levels, BMI and Gleason scores, and PD-1 among patients with prostate cancer and controls. However, elevated levels of PD-L1 were significantly associated with raised Gleason scores among patients with prostate cancer with a p-value of <0.001.

Conclusions

Elevated PD-L1 levels were statistically significantly linked to high Gleason scores. These results may guide clinicians in assessing the prognosis of patients individually and selecting suitable patients that will make favorable candidates for anti-PD-L1 immunotherapy.

Background

Prostate cancer is the second most frequently diagnosed cancer in men worldwide, accounting for approximately 15% of all new cancer diagnoses in men (1). In 2020, the Global Cancer Observatory (Globocan) report indicated an annual worldwide incidence of 1.4 million prostate cancer cases, with approximately 375,304 deaths (2). Reports indicate that men of African ancestry suffer disproportionately from prostate cancer at a rate almost twice as high as men of European origin, irrespective of new treatment modalities (3–5).
The mainstay therapy for advanced prostate cancer remains androgen deprivation therapy (ADT)(6). Among patients with metastatic prostate cancer, various treatment options for metastatic castration-resistant prostate cancer (mCRPC) such as hormonal therapy, chemotherapy, and radiopharmaceuticals have shown significantly increased overall survival (OS). Still, these ultimately develop resistance (7, 8).

In the last decade, the introduction of immunotherapy which works through the augmentation of immune responses against cancers has yielded promising results and considerably changed the treatment landscape owing to its efficacy and minimal side effects (9, 10). Thus, immune checkpoint inhibitors have emerged as a complementary treatment arm in cancer clinical care and research (11, 12). The co-inhibitory receptor programmed death1 (PD-1) is expressed on activated T cells and B cells. Upon binding to its ligands PD-L1, which is expressed on macrophages, dendritic cells and some tumour cells, T cell activation is downregulated by inhibiting CD28 signaling (13). Besides being expressed on cell membranes, several extracellular (soluble) forms of PD-L1, including spliced variants and proteolytic cleavage forms, have been reported in various types of cancer(14). Soluble PD-L1 can bind to PD1 on T cells and suppress anti-tumour immunity, thus facilitating tumour growth. Blocking the PD1/PD-L1 interaction using immune checkpoint inhibitors have been shown to reduce tumour growth and increase overall survival of patients. (15).

Anti-PD1 antibody immunotherapy (e.g.nivolumab) and anti-PD-L1 antibody (e.g., atezolizumab) have demonstrated improved response rates and overall survival among patients with melanoma and renal cell carcinoma, respectively(16, 17).

The ongoing clinical trials show that immunotherapy might provide a promising approach for the future treatment of prostate cancer (18). Studies indicate that PD-L1 expression is up-regulated in prostate cancer tissues compared to paired benign prostate tissues. Similarly, high levels of PD-L1 expression have been shown to have a positive correlation with high Gleason scores and androgen receptor expression in patients with aggressive primary prostate cancer (19–21).

This study assessed the circulating levels of immune checkpoint molecules, PD-1 and PD-L1, among prostate cancer patients and normal healthy controls and their association with age, BMI, plasma PSA, and Gleason scores at the Uganda Cancer Institute.

**Methods**

**Study population**

This was a case-control study in which 86 men, 57 prostate cancer patients on androgen deprivation therapy, and 29 normal healthy controls were recruited from January 2020 to June 2020 at the Uganda Cancer Institute, Kampala, Uganda. All study participants were aged 40 years and above. Controls were men aged 40 years and above with no history of prostate cancer and with a PSA of less than 4ng/ml. The cases were men with a histological diagnosis of Prostate cancer and on androgen deprivation therapy.
Study procedures

A pre-designed questionnaire was used to obtain demographic data and the medical history of study participants. Six (6) mls of blood in an ethylenediaminetetraacetate (EDTA) anti-coagulated tube was collected by a trained study nurse from each study participant. Blood samples were transported within one hour to the laboratory for processing. This study obtained ethical approval from the School of Biomedical Sciences Higher Degrees Research and Ethics Committee (REF: SBS-HDREC-779) and the Uganda National Council for Science and Technology (UNCST). All study participants provided written informed consent before enrolment into the study.

Plasma collection and Immunoassays

Separation of platelet-poor plasma

All laboratory procedures and tests were carried out in the Translational Research laboratory at the Infectious Diseases Institute, Makerere University, Kampala, Uganda. On reception in the laboratory, whole blood samples were immediately centrifuged at 6^0^C at a speed of 1000g for 10 minutes. The supernatant was collected in a sterile falcon tube and centrifuged again at 1600g for 10 minutes at 6^0^C. The resulting supernatant was then separated into two aliquots and stored at -80^0^C for later use to perform the Immunoassays.

ELISA Immunoassays

Plasma levels of immune checkpoint regulators were measured in pg./ml and commercially procured control samples for each analyte were assayed in parallel to ensure good results. Stored plasma samples were retrieved and thawed at 4-8^0^C. Immunoassays were performed in duplicates using Human checkpoint markers PD-1 and PD-L1 Quantikine ELISA Kits (R&D Systems), following the manufacturer's instructions.

Statistical analysis

Categorical variables (demographic and clinical factors) were summarized as absolute numbers and proportions. Continuous variables (plasma concentration of cytokines) were summarized as medians and interquartile ranges. Mann-Whitney U-test was used to compare continuous variables and Fisher's exact test for comparing categorical variables. The association of immune checkpoint molecules with different ages, Gleason score, PSA, and BMI was explored using conditional linear regression. All analyses were performed using STATA16.

Results

Clinico-demographic factors in Prostate cancer patients and controls
The median age was 70 years in cases and 59 years in the control group. The median BMI was 20.84 in the cases and 19.45 in the control group. The majority of the participants, 49.43% for cases and 68.97% for controls were in the normal BMI range of 18.5-24.9. The median PSA was 33.01ng/ml and 1.8ng/ml among cases and controls, respectively. Among the cases, the majority (31.58%) had a PSA of >100ng/ml. 43.86% of the prostate cancer patients had advanced prostate cancer with Gleason scores of 8-10. Full description of clinical and demographics characteristics in table 1.

Table 1; Clinical characteristics of Prostate cancer patients and controls

Plasma levels of immune checkpoint molecules

The median concentrations of the PD-1 and PD-L1 were generally higher in cases than in controls. We found significant differences in the plasma concentrations of PD-L1 and PD-1 immune checkpoint molecules between Prostate cancer cases and normal healthy controls with *p*-values of 0.001 and 0.017, respectively, as seen in Figure 1. We found high levels of PD-L1 were significantly associated with raised Gleason scores among patients with prostate cancer with a *p*-value of <0.001 (Table 3).

However, the study found no significant association between age, plasma PSA levels, BMI and Gleason scores, and PD-1 checkpoint molecule among patients with prostate cancer and controls.

Figure 1; Median concentrations of immune checkpoint molecules in prostate cancer patients and controls.

Table 2; Median plasma concentrations of immune checkpoint molecules in Prostate cancer patients and controls.

Table 3: Association between immune checkpoint molecules and age, BMI, PSA, and Gleason score among Prostate cancer patients and controls.

Discussion

This was the first study to assess the association between soluble PD-1/PD-L1 levels and prostate cancer clinical characteristics in African populations. This study evaluated the circulating concentrations of immune checkpoint molecules PD-1 and PD-L1 and their association with PSA levels, Gleason scores, age, and BMI among patients with Prostate cancer and controls at the Uganda Cancer Institute. Consistent with previous studies, our results suggest a significant association between PD-L1 levels and high Gleason scores, prognostic of aggressive tumour behavior in prostate cancer (20, 22–24)

This finding further suggests that the PD-1/PD-L1 pathway activation supports the evasion of the anti-tumour immune response, driving tumour pathogenesis. The probability of anti-tumour immune response to anti-PD-1/anti-PD-L1 antibody therapy is associated with the expression of PD-L1 on the tumour cell surface (24–27).
Different mechanisms by which PD-L1-expressing cells evade T-cell immunity have been hypothesized, namely: inducing (1) apoptosis, (2) T cell energy, or (3) functional exhaustion of T-cells, (4) forming a molecular shield to keep lysis off tumour cells, (5) increasing production of the immunosuppressive cytokine IL-10, and (6) facilitating Treg cell-mediated suppression(28)(29). Increased expression of PD-L1 on tumour cells has previously been described for several malignancies, including glioblastoma, pancreatic, ovarian, breast, renal, head, and neck, esophageal, and non–small cell lung cancer. PD-L1 expression has also been associated with poor prognosis and adverse Clinico-pathological characteristics (21, 30, 31). A study by Gevensleben et al., 2016 provided early evidence of abundant expression of PD-L1 in primary prostate cancer as a common occurrence and is a negative predictor for BCR-free survival (23, 32). Similarly, Heng Li et al. 2019 and colleagues looked at the expression of PD-1/PD-L1 in a retrospective cohort of men with prostate cancer who received adjuvant hormonal therapy (AHT) after radical prostatectomy (RP). They found moderate to high PD-L1 expression in 49.6% of primary prostate cancers after radical prostatectomy. In addition, PD-L1 expression was significantly associated with reduced biochemical recurrence-free survival (33).

Topalian et al. 2012 and colleagues carried out an immune-histochemical assessment of PD-L1 in pretreatment cancer specimens from 42 patients. They revealed that objective response to treatment was seen exclusively in (36%) PD-L1–positive tumours (34). Bishop et al. 2015 and colleagues recently reported that CRPC patients resistant to enzalutamide showed elevated levels of PD-L1 in blood. The authors further concluded that PD-L1 expression on tumour cells might be a possible mechanism of non-AR–driven resistance to enzalutamide (22).

There is a need for predictive biomarkers that can identify patients who will benefit most from anti-PD-1/PD-L1 immunotherapy. Our study and many others provide evidence of PD-L1 expression as a promising predictive biomarker for patients likely to benefit from therapeutic blockade of PD-1/PD-L1 immunotherapies (35, 36). Based on our results, we provided credible evidence that Prostate cancer patients with higher Gleason scores were more likely to have higher levels of PD-L1 expression with statistical significance.

These patients are more likely to benefit from blocking the PD-1/PD-L1 pathway.

**Conclusion**

In conclusion, our study confirms that circulating levels of PD-L1 are significant independent prognostic factors in patients with prostate cancer. In addition, PD-L1 overexpression was statistically significantly linked to high Gleason scores. These results may guide clinicians in assessing the prognosis of patients individually or by selecting suitable patients that will be favorable candidates to receive anti-PD-1/PD-L1 immunotherapy. We recommend extensive prospective cohort studies to validate these findings further.

**Abbreviations**
PD-1  
Programmed cell death - 1

PD-L1  
Programmed cell death ligand -1

PSA  
Prostate-specific antigen

ADT  
Androgen Deprivation Therapy

ELISA  
Enzyme-Linked Immunosorbent Assay

EDTA  
Ethylene Diamine Tetra Acetate

BMI  
Body Mass Index

Declarations

Authors’ contributions

PK, OJS, and NN contributed to the conceptualization of the manuscript. CN and MA contributed to the running of the laboratory assays. PK and KS collected, cleaned, analyzed data and drafted manuscript. HK, SK, MJ, SJR, KS and JO read and reviewed the manuscript information and data. All authors read and approved the final version of the manuscript.

Disclosure of potential conflicts of interest

The authors declare that they have no conflict of interests.

Research involving Human participants and/or Animals and Ethical Approval

This study obtained ethical approval from the School of Biomedical Sciences Higher Degrees Research and Ethics Committee (REF: SBS-HDREC- 779) and the Uganda National Council for Science and Technology.

Informed consent

All study participants provided written informed consent before enrolment into the study.

Acknowledgements

We want to thank all study participants at the Uganda Cancer Institute who consented to participate in this study.

Availability of data and materials
All data files used in this manuscript article [and its supplementary information files] are available via figshare https://doi.org/10.6084/m9.figshare.14904870.v1

Funding

PK receives funding for doctoral studies from the African Development bank under Uganda Cancer Institute support training grant Project ID P-Z1-IB0-024 and is also supported by the Office of the Director, National Institutes of Health (OD), National Institute of Dental & Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Heart, Lung, And Blood Institute (NHLBI), Fogarty International Center (FIC), National Institute on Minority Health and Health Disparities (NIMHD) grant number D43TW010132. In addition D43TW010132 is funded in part (SJR) by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID). Its contents are solely the authors' responsibility and do not necessarily represent the supporting offices' official views.

References

1. James N, Lee N, Horton R (2021) Announcing the Lancet Commission on Prostate Cancer. Lancet [Internet]. ;397(10288):1865–6. Available from: http://dx.doi.org/10.1016/S0140-6736(21)01020-5
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. ; Available from: http://dx.doi.org/10.3322/CAAC.21660
3. Lewis DD, Cropp CD (2020) The Impact of African Ancestry on Prostate Cancer Disparities in the Era of Precision Medicine. Genes (Basel) [Internet]. ;11(12):1471. Available from: http://dx.doi.org/10.3390/GENES11121471
4. Koga Y, Song H, Chalmers ZR, Newberg J, Kim E, Carrot-Zhang J et al (2020) Genomic Profiling of Prostate Cancers from Men with African and European Ancestry. Clin Cancer Res [Internet]. ;26(17):4651–60. Available from: http://dx.doi.org/10.1158/1078-0432.CCR-19-4112
5. Tan S-H, Petrovics G, Srivastava S (2018) Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. Int J Mol Sci [Internet]. ;19(4):1255. Available from: http://dx.doi.org/10.3390/IJMS19041255
6. Payne H, Mason M (2011) Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localized and locally advanced prostate cancer: recent developments. Br J Cancer [Internet]. ;105(11):1628–34. Available from: http://dx.doi.org/10.1038/BJC.2011.385
7. Powers E, Karachaliou GS, Kao C, Harrison MR, Hoimes CJ, George DJ et al (2020) Novel therapies are changing treatment paradigms in metastatic prostate cancer. J Hematol Oncol [Internet]. ;13(1). Available from: http://dx.doi.org/10.1186/S13045-020-00978-Z
8. Teo MY, Rathkopf DE, Kantoff P (2019) Treatment of Advanced Prostate Cancer. Annu Rev Med [Internet]. ;70(1):479–99. Available from: http://dx.doi.org/10.1146/ANNUREV-MED-051517-011947
9. Farkona S, Diamandis EP, Blasutig IM (2016) Cancer immunotherapy: the beginning of the end of cancer? BMC Med [Internet]. ;14(1). Available from: http://dx.doi.org/10.1186/S12916-016-0623-5

10. Rusch T, Bayry J, Werner J, Shevchenko I, Bazhin AV (2017) Immunotherapy as an Option for Cancer Treatment. Arch Immunol Ther Exp (Warsz) [Internet]. ;66(2):89–96. Available from: http://dx.doi.org/10.1007/S00005-017-0491-5

11. Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol [Internet]. ;62:29–39. Available from: http://dx.doi.org/10.1016/J.INTIMP.2018.06.001

12. Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS (2018) Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol [Internet]. ;15(8):477–94. Available from: http://dx.doi.org/10.1038/S41571-018-0046-7

13. Xiong W, Gao Y, Wei W, Zhang J (2021) Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends in Cancer.

14. Zhu X, Lang J, Soluble (2017) PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget 8(57):97671

15. Jain P, Jain C, Velcheti V (2018) Role of immune-checkpoint inhibitors in lung cancer. Ther Adv Respir Dis [Internet]. ;12:175346581775007. Available from: http://dx.doi.org/10.1177/1753465817750075

16. Koppolu V, Rekha Vasigala V (2018) Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. J Cancer Res Ther [Internet]. ;0(0):0. Available from: http://dx.doi.org/10.1177/175628722095140

17. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet [Internet]. ;387(10031):1909–20. Available from: http://dx.doi.org/10.1016/S0140-6736(16)00561-4

18. Handa S, Hans B, Goel S, Bashorun HO, Dovey Z, Tewari A (2020) Immunotherapy in prostate cancer: current state and future perspectives. Ther Adv Urol [Internet]. ;12:175628722095140. Available from: http://dx.doi.org/10.1177/1756287220951404

19. Xian P, Ge D, Wu VJ, Patel A, Tang WW, Wu X et al (2019) PD-L1 instead of PD-1 status is associated with the clinical features in human primary prostate tumors. Am J Clin Exp Urol 7(3):159

20. Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T et al (2016) The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res 22(8):1969–1977

21. Li Y, Huang Q, Zhou Y, He M, Chen J, Gao Y et al (2019) The clinicopathologic and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with prostate cancer: a systematic review and meta-analysis. Front Pharmacol 9:1494

22. Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN et al (2015) PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget 6(1):234
23. Gevensleben H, Holmes EE, Goltz D, Dietrich J, Sailer V, Ellinger J et al (2016) PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget 7(48):79943
24. Richter I, Jirasek T, Havlickova I, Curcikova R, Samal V, Dvorak J et al (2018) The expression of PD-L1 in patients with castrate prostate cancer treated with enzalutamide. Bone 29:87–89
25. Han Y, Liu D, Li L (2020) PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10(3):727
26. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264
27. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al (2010) Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167
28. Ostrand-Rosenberg S, Horn LA, Haile ST (2014) The programmed death-1 immune-suppressive pathway: barrier to anti-tumor immunity. J Immunol 193(8):3835–3841
29. Nowicki TS, Hu-Lieskovan S, Ribas A (2018) Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J 24(1):47
30. Yi M, Niu M, Xu L, Luo S, Wu K (2021) Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol 14(1):1–13
31. Yu W, Hua Y, Qiu H, Hao J, Zou K, Li Z et al (2020) PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis 11(7):1–16
32. Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T et al (2015) The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clin Cancer Res [Internet]. ;22(8):1969–77. Available from: http://dx.doi.org/10.1158/1078-0432.CCR-15-2042
33. Li H, Wang Z, Zhang Y, Sun G, Ding B, Yan L et al (2019) The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy. J Cancer [Internet]. ;10(14):3102–11. Available from: http://dx.doi.org/10.7150/JCA.30384
34. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454
35. Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X et al (2018) Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer [Internet]. ;17(1). Available from: http://dx.doi.org/10.1186/S12943-018-0864-3
36. Shien K, Papadimitrakopoulou VA, Wistuba II (2016) Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer. Lung Cancer [Internet]. ;99:79–87. Available from: http://dx.doi.org/10.1016/J.LUNGCAN.2016.06.016
Table 1: Clinical characteristics of Prostate cancer patients and controls

| Clinical characteristics | Cases n(57) | Controls n(29) |
|--------------------------|------------|---------------|
| **Age**                  |            |               |
| Median(IQR)              | 70 (44-89) | 59 (44-82)    |
| 41-65yrs                 | 17 (29.82%)| 18 (62.07%)   |
| 66-75yrs                 | 26 (45.61%)| 6 (20.69%)    |
| >75yrs                   | 13 (22.81%)| 5 (17.24%)    |
| **BMI (kg/m2)**          |            |               |
| Median(IQR)              | 20.84 (16.03-27.61) | 19.45 (17.22-22.46) |
| <18.5                    | 8 (14.04%) | 9 (31.03%)    |
| 18.5-24.9                | 43 (49.43%)| 20 (68.97%)   |
| 25-29.9                  | 6 (10.53%) | 0 (0.00%)     |
| 30 and above             | 0 (0.00%)  | 0 (0.00%)     |
| **Gleason Score**        |            | N/A           |
| Median(IQR)              | 7 (6-10)   | -             |
| 6 (3+3)                  | 13 (22.8%) | -             |
| 7 (3+4) or (4+3)         | 19 (33.33%)| -             |
| 8 (4+4)                  | 10 (17.54%)| -             |
| 9 (4+5)                  | 9 (15.79%) | -             |
| 10 (5+5)                 | 6 (10.53%) | -             |
| **Plasma PSA (ng/ml)**   |            |               |
| Median (IQR)             | 33.01 (0.024 - 10000) | 1.8 (0.134-4.00) |
| ≤ 4                      | 16 (28.07%)| 29 (100%)     |
| 5-20                     | 9 (15.79%) | 0 (0.00%)     |
| 20-100                   | 14 (24.56%)| 0 (0.00%)     |
| >100                     | 18 (31.58%)| 0 (0.00%)     |

Table 2. Plasma levels of PD-1 and PD-L1 between cases and controls

| Immune check point marker | Cases Median (IQR) | Controls Median (IQR) | p-value |
|---------------------------|--------------------|-----------------------|---------|
| PD-1 (pg./ml)             | 0.596 (0.319 - 0.842) | 0.355 (0.245-0.616)   | 0.0170  |
| PD-L1 (pg./ml)            | 0.285(0.250 -0.340) | 0.035(0.029-0.045)    | 0.0101  |

Table 3: Association between immune checkpoint molecules and age, BMI, PSA, and Gleason score among Prostate cancer patients and controls.
| Participants | Immune Checkpoint Molecules | Age p-value | BMI p-value | PSA p-value | Gleason score p-value |
|--------------|-----------------------------|-------------|-------------|-------------|----------------------|
|              |                             | correlation | correlation | correlation | correlation          |
|              |                             | co-efficient (r) | co-efficient (r) | co-efficient (r) | co-efficient (r) |
| Cases        | sPD-1                       | 0.800       | 0.697       | 0.758       | 0.278               |
|              | sPD-L1                      | 0.492       | 0.247       | 0.485       | **0.014**           |
|              |                             | (-0.0222)   | ( 0.0396 )  | ( 0.0180 )  | ( 0.1425 )          |
| Controls     | sPD-1                       | 0.397       | 0.087       | 0.819       | N/A                 |
|              | sPD-L1                      | 0.039       | 0.056       | 0.606stata  | N/A                 |
|              |                             | (-0.0465)   | ( 0.3003 )  | ( -0.0538 ) | N/A                 |

**Figures**

**Figure 1**

Median concentrations of immune checkpoint molecules in prostate cancer patients and controls.
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryfileDataset.xlsx